Patients prefer video in study of Nexium promotion

Share this article:
Results of a survey conducted last week showed that patients preferred online video over podcasts in AstraZeneca's "Living with Heartburn" promotional efforts featured on About.com.
 
According to About.com's general manger, health Marjorie Martin, online video performed extremely well in a study of 893 visitors to About.com who were asked to examine content related to gastroesophageal reflux disease (GERD) sponsored by AstraZeneca.

"It could have been the presence of visuals that had the (greatest) impact," Martin told an audience of pharma marketers at the Center for Business Intelligence’s Patient-Centered Marketing for the Bio/Pharmaceutical and Medical Device Industry conference in West Conshohocken, PA on Monday.
 
Martin said further details of the survey are to be released soon.
 
About.com and AstraZeneca first teamed up in late 2006 to launch a six-part podcast series dubbed "Living with Heartburn" to support the Nexium brand. The companies have also collaborated on video for the effort to help educate consumers on being tested for GERD and coping with the disease.    

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...